Almost one in three newly approved drugs in the United States turns out to have a safety issue after it is allowed on the market, US researchers said Tuesday. While these issues are rarely serious enough to get the drug pulled from the marketplace, researchers said-new drugs should be monitored for years after they are released to the public. Cutting-edge therapies known as biologics, psychiatric drugs, and medicines that were fast-tracked by the US Food and Drug Administration were most likely to require additional safety warnings after approval, said the report in Journal of the American Medical Association (JAMA).



More...